PharmaBlock Sciences Nanjing Inc
SZSE:300725
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PharmaBlock Sciences Nanjing Inc
Total Equity
PharmaBlock Sciences Nanjing Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
Total Equity
¥7.1B
|
CAGR 3-Years
41%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Equity
¥35.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Equity
¥61.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
20%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Equity
¥40B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Total Equity
¥32.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Equity
¥3.9B
|
CAGR 3-Years
127%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
PharmaBlock Sciences Nanjing Inc
Glance View
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
See Also
What is PharmaBlock Sciences Nanjing Inc's Total Equity?
Total Equity
7.1B
CNY
Based on the financial report for Sep 30, 2025, PharmaBlock Sciences Nanjing Inc's Total Equity amounts to 7.1B CNY.
What is PharmaBlock Sciences Nanjing Inc's Total Equity growth rate?
Total Equity CAGR 5Y
51%
Over the last year, the Total Equity growth was 146%. The average annual Total Equity growth rates for PharmaBlock Sciences Nanjing Inc have been 41% over the past three years , 51% over the past five years .
